2009-12-01
Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma
Publication
Publication
British Journal of Cancer , Volume 101 - Issue 12 p. 1995- 2004
Background: We evaluated the efficacy of imatinib mesylate in addition to hydroxyurea in patients with recurrent glioblastoma (GBM) who were either on or not on enzyme-inducing anti-epileptic drugs (EIAEDs). Methods: A total of 231 patients with GBM at first recurrence from 21 institutions in 10 countries were enrolled. All patients received 500 mg of hydroxyurea twice a day. Imatinib was administered at 600 mg per day for patients not on EIAEDs and at 500 mg twice a day if on EIAEDs. The primary end point was radiographic response rate and secondary end points were safety, progression-free survival at 6 months (PFS-6), and overall survival (OS). Results: The radiographic response rate after centralised review was 3.4%. Progression-free survival at 6 months and median OS were 10.6% and 26.0 weeks, respectively. Outcome did not appear to differ based on EIAED status. The most common grade 3 or greater adverse events were fatigue (7%), neutropaenia (7%), and thrombocytopaenia (7%). Conclusions: Imatinib in addition to hydroxyurea was well tolerated among patients with recurrent GBM but did not show clinically meaningful anti-tumour activity.
| Additional Metadata | |
|---|---|
| , , , | |
| doi.org/10.1038/sj.bjc.6605411, hdl.handle.net/1765/24592 | |
| British Journal of Cancer | |
| Organisation | Erasmus MC: University Medical Center Rotterdam |
|
Reardon, D. A., Dresemann, G., Taillibert, S., Campone, M., van den Bent, M., Clement, P., … Nikolova, Z. (2009). Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. British Journal of Cancer, 101(12), 1995–2004. doi:10.1038/sj.bjc.6605411 |
|
